Kendra, Kari L <br/><br/>
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.  [electronic resource] 

 -  Molecular cancer therapeutics  Feb 2015 
 - 461-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-14-0431  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Indazoles<br/>Leukocyte Count<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplasms--blood<br/>Paclitaxel--adverse effects<br/>Pyrimidines--adverse effects<br/>Sulfonamides--adverse effects